From: Detection of autoantibodies in a point-of-care rheumatology setting
Disease/condition | Autoantibody | Change | Clinical prediction |
---|---|---|---|
Systemic lupus erythematosus | Anti-dsDNA | ⇑ | |
Anti-dsDNA | ⇓ | Active flare [18] | |
Anti-nucleosome | ⇑ | ||
Anti-C1q | ⇑ | ||
Anti-NMDA-R | ⇑ | ||
Anti-NMDA-R | ⇓ | ||
Anti-CRP | ⇑ | Lupus nephritis/response to therapy [28] | |
Anti-interferon-α | ⇓ | Inactive disease [29] | |
Systemic vasculitis | Anti-PR3 | ⇑ | |
Anti-MPO | ⇑ | ||
Anti-GBM | ⇑ | ||
Scleroderma | Anti-topoisomerase I | ⇑ | |
Rheumatoid arthritis | Anti-drug (adalimumab) | ⇑ | Treatment failure [40] |
Antiphospholipid syndrome/SLE | Anti-phospholipid | ⇑ | |
Necrotizing myopathy | Anti-signal recognition particle | ⇑ | Decreased muscle strength, increased creatine kinase activity [44] |
Thrombotic thrombocytopenic purpura | Anti-ADAMTS13 antibodies | ⇑ | |
Pregnancy in SLE | Anti-Ro(SSA)/anti-Ro52 | ⇑ | |
Anti-La(SSB) | ⇑ | Neonatal lupus [49] | |
Autoantibody serum screening | Anti-DFS70 | ⇑ |